Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017–2019)

Abstract

Objectives: The antimicrobial activity of tedizolid and comparators was evaluated against a large worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae isolates recovered from patients with pneumonia. Methods: Clinical isolates were collected from patients in 96 medical centres in the Asia-Pacific region, Europe, Latin America and the USA between 2017 and 2019, and tested for susceptibility by reference broth microdilution. Results: The most active agents against S. aureus (n = 4667) were tedizolid (100.0% susceptible), linezolid (100.0% susceptible), ceftaroline (96.2% susceptible) and vancomycin (100.0% susceptible), but only tedizolid, linezolid and vancomycin retained activity against >95% of meticillin-resistant S. aureus isolates from all regions. In general, linezolid, ceftriaxone, ceftaroline, levofloxacin, penicillin and vancomycin showed susceptibility rates >95% against S. pneumoniae (n = 3008). However, only linezolid, ceftaroline, levofloxacin and vancomycin remained active (>95% susceptibility) against isolates displaying penicillin-non-susceptible or multidrug-resistant phenotypes. Penicillin-non-susceptible S. pneumoniae isolates were recovered less frequently from patients aged <5 years compared with other age groups. Conclusion: The in-vitro data presented here confirm the high potency of tedizolid against S. aureus and S. pneumoniae causing pneumonia worldwide. There is a need for further clinical evaluations of tedizolid for treating pneumonia caused by these pathogens.

Keywords

• MRSA
• Penicillin-non-susceptible
• Pneumococcus
• CAP
• Oxazolidinone